Inflammatory bowel disease (IBD) is a chronic condition that significantly affects the quality
of life of its patients. Biologic drugs have been the mainstay treatment in the management of …

Biologics and immunomodulators (IMM) are generally considered the most effective
therapies for the treatment of ulcerative colitis and Crohn's disease. However, despite the …

Inflammatory bowel disease (IBD) treatment targets have progressed over time from clinical
response to clinical and endoscopic remission. Several data have shown a positive …

Background: Inflammatory Bowel Disease (IBD) impacts millions worldwide, presenting a
major challenge to healthcare providers and patients. The advent of biologic therapies has …

Background: Therapeutic drug monitoring (TDM) is a decision-making tool for optimizing the
use of certain therapies. In this article, the authors review the role of proactive TDM of …

For all biologics in IBD, there is a positive correlation between drug concentrations and
favorable therapeutic outcomes. Reactive TDM is the new standard of care for optimizing …

During the past decade, we have entered an era of biologics for the treatment of Crohn's
disease and ulcerative colitis. The therapeutic goal of inflammatory bowel disease (IBD) …

The implementation of therapeutic drug monitoring (TDM) in the inflammatory bowel disease
practice has evolved over the years. In the early days, the focus was merely on measuring …

Background & Aims Proactive therapeutic drug monitoring (TDM) has been proposed to
improve outcomes in patients with inflammatory bowel disease (IBD) treated with tumor …

Therapeutic drug monitoring (TDM) is a useful strategy to optimize biologic medications for
inflammatory bowel disease not responsive to standard dosing regimens. TDM is cost …